Scalper1 News
Monday brought a surprising turn to the twisting story of hepatitis C treatments, as pharmacy giant CVS Health said it will offer exclusive coverage for Gilead Sciences’ hep C drugs. But the key issue of price remained unanswered. The deal seemed to counterattack one cut two weeks ago between pharmacy benefit manager Express Scripts (ESRX) and AbbVie (ABBV), days after the FDA OK’d AbbVie’s four-drug Viekira Pak for genotype 1 of the Scalper1 News
Scalper1 News